Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDURA vs PRECOSE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.
Alpha-glucosidase inhibitor; competitively inhibits brush-border alpha-glucosidases in the small intestine, delaying carbohydrate digestion and reducing postprandial hyperglycemia.
Hypertension,Benign prostatic hyperplasia
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Prevention of type 2 diabetes in patients with impaired glucose tolerance
Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.
Initial: 25 mg orally three times daily with the first bite of each main meal; maintenance: 50-100 mg three times daily; maximum 100 mg three times daily.
Terminal elimination half-life is approximately 22 hours, allowing once-daily dosing; peak effect on blood pressure occurs at 2-6 hours post-dose.
Terminal elimination half-life is approximately 2 hours for the parent drug, but clinical effect persists due to prolonged binding to intestinal alpha-glucosidases.
Extensively metabolized in the liver via O-demethylation and hydroxylation; CYP3A4 is the major enzyme involved.
Not extensively metabolized; primarily excreted unchanged in the urine as active drug. Small fraction undergoes intestinal metabolism by digestive enzymes.
Primarily hepatic metabolism (approx. 60-70%) with biliary excretion of metabolites; renal excretion accounts for about 30-40% of the dose, mainly as metabolites with <5% unchanged drug.
Primarily excreted in feces (about 85%) as unchanged drug and metabolites, with less than 2% excreted renally as active metabolites.
98-99% bound to plasma proteins (primarily albumin).
Low protein binding, approximately 5%, primarily to albumin.
0.5-1.0 L/kg (approximately 50-70 L in adults); indicates extensive extravascular distribution.
Volume of distribution is approximately 0.3 L/kg, indicating minimal distribution into tissues and predominantly confined to extracellular fluid.
Oral bioavailability is approximately 65% (range 43-81%) with minimal first-pass effect.
Oral bioavailability is low, approximately 2%, due to local action in the gastrointestinal tract and minimal systemic absorption.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, start with 0.5 mg daily and titrate cautiously due to increased sensitivity.
No dose adjustment recommended for mild to moderate renal impairment. Contraindicated in severe renal impairment (e GFR <25 m L/min/1.73 m²).
Child-Pugh A: Start at 0.5 mg daily. Child-Pugh B or C: Contraindicated due to extensive hepatic metabolism.
No dose adjustment recommended for mild hepatic impairment. Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); avoid use.
Safety and efficacy not established in pediatric patients; use not recommended.
Not recommended for pediatric patients (safety and efficacy not established).
Initiate at 0.5 mg daily due to increased risk of orthostatic hypotension. Titrate slowly based on tolerability and response.
No specific dose adjustment required; monitor renal function due to age-related decline. Start at low end of dosing range (25 mg three times daily).
None
None.
Orthostatic hypotension and syncope, especially with first dose,Use with caution in patients with hepatic impairment,Risk of priapism,Intraoperative floppy iris syndrome during cataract surgery
Hypoglycemia: Acarbose does not cause hypoglycemia when used alone, but may increase risk when combined with sulfonylureas or insulin. Hypoglycemic episodes should be treated with glucose (dextrose), not sucrose.,Hepatic injury: Rare cases of acute hepatitis, jaundice, and fulminant hepatic failure; monitor liver function tests.,Renal impairment: Contraindicated in patients with Cr Cl <25 m L/min.,Gastrointestinal effects: Frequently causes flatulence, diarrhea, and abdominal discomfort due to undigested carbohydrates; these effects may diminish with continued use.
Hypersensitivity to doxazosin or other quinazolines
Hypersensitivity to acarbose or any component,Diabetic ketoacidosis,Cirrhosis,Inflammatory bowel disease,Colonic ulceration,Partial intestinal obstruction or predisposition to intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Conditions that may deteriorate as a result of increased intestinal gas formation (e.g., Roemheld syndrome),Severe renal impairment (Cr Cl <25 m L/min)
Avoid grapefruit and grapefruit juice as they may increase doxazosin levels. Take with food to reduce gastrointestinal upset. No other significant food interactions.
Avoid sucrose and table sugar as they may worsen GI side effects. Dietary carbohydrates increase efficacy but also GI side effects. Precose alone does not cause hypoglycemia; however, if used with insulin or sulfonylureas, hypoglycemia must be treated with glucose (dextrose) because absorption of complex sugars and sucrose is inhibited.
Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia from maternal hypotension. Avoid use in pregnancy unless benefit outweighs risk.
Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 200 mg/kg/day (6-15 times human exposure). No adequate human studies; risk cannot be ruled out.
Excreted in human milk; M/P ratio unknown. Caution due to potential for hypotension in nursing infants. Use only if essential.
Unknown if excreted in human milk. Caution advised. M/P ratio not established.
No established dose adjustments for pregnancy; use lowest effective dose due to potential for increased clearance and changes in volume of distribution.
No dose adjustment recommended; monitor glucose control closely as pharmacokinetics may change; insulin often preferred.
CARDURA (doxazosin) is an alpha-1 blocker used for hypertension and benign prostatic hyperplasia (BPH). First-dose syncope is more common with immediate-release (IR) than extended-release (GITS). Start IR at 1 mg at bedtime and titrate slowly. GITS formulation minimizes orthostatic effects. Monitor blood pressure carefully in elderly patients. May cause intraoperative floppy iris syndrome (IFIS) during cataract surgery; do not stop therapy preoperatively. Avoid use in patients with orthostatic hypotension or micturition syncope.
Precose (acarbose) is an alpha-glucosidase inhibitor that delays carbohydrate absorption. It is most effective for postprandial hyperglycemia. Must be taken with the first bite of each main meal. Avoid use in patients with inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction. Can cause elevated liver enzymes; monitor LFTs every 3 months during first year. Hypoglycemia from other agents should be treated with glucose (not sucrose) because sucrase is inhibited.
Take the first dose at bedtime to minimize dizziness. Sit or lie down if you feel lightheaded.,Avoid sudden position changes; rise slowly from sitting or lying positions.,May cause dizziness, drowsiness, or blurred vision. Do not drive until you know how CARDURA affects you.,For BPH, it may take up to 2 weeks to improve symptoms. Do not stop medication abruptly.,Inform your surgeon if you are scheduled for cataract surgery; CARDURA may affect eye surgery outcomes.,Avoid alcohol, which can worsen side effects like dizziness and low blood pressure.,For hypertension, continue regular monitoring with your healthcare provider.
Take this medication with the first bite of each main meal.,If you experience low blood sugar, treat it with glucose tablets or milk, not fruit juice or regular soda.,Common side effects include flatulence, diarrhea, and abdominal pain, which often decrease with time.,Do not take this drug if you have severe kidney problems or certain bowel diseases.,Report any signs of liver problems (yellow skin/eyes, dark urine, abdominal pain) immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDURA vs PRECOSE, answered by our medical review team.
CARDURA is a Alpha-1 Blocker Antihypertensive that works by Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.. PRECOSE is a Alpha-Glucosidase Inhibitor Antidiabetic that works by Alpha-glucosidase inhibitor; competitively inhibits brush-border alpha-glucosidases in the small intestine, delaying carbohydrate digestion and reducing postprandial hyperglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDURA and PRECOSE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDURA is: Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.. The standard adult dose of PRECOSE is: Initial: 25 mg orally three times daily with the first bite of each main meal; maintenance: 50-100 mg three times daily; maximum 100 mg three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDURA and PRECOSE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDURA is classified as Category C. Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia. PRECOSE is classified as Category C. Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 200 mg/kg/day (6-15 times human exposure). No adequate human studies; risk cannot be ruled out.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.